Get started
Author

Yufei Bi

Observed name: Yu-Fei Bi
ORCID: 0009-0008-6871-8322
Observed ORCID: 0009-0008-6871-8322
OpenAlex ID: A5043042743
Nav1.7 as a chondrocyte regulator and therapeutic target for osteoarthritis
2024 · Wenyu Fu, Dmytro Vasylyev, et al. · Nature · 115
Gut microbiota dysbiosis with hepatitis B virus liver disease and association with immune response
2023 · Fengna Yan, Qun Zhang, et al. · Frontiers in Cellular and Infection Microbiology · 75
PDF
Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis
2019 · Ronghan Liu, Yuehong Chen, et al. · Annals of the Rheumatic Diseases · 59
PDF
Neutrophil-to-high-density-lipoprotein-cholesterol ratio and mortality among patients with hepatocellular carcinoma
2023 · Ke Shi, Jie Hou, et al. · Frontiers in Nutrition · 41
Association between probiotic therapy and the risk of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis
2023 · Ke Shi, Qun Zhang, et al. · Frontiers in Cellular and Infection Microbiology · 20
Effects of adjuvant huaier granule therapy on survival rate of patients with hepatocellular carcinoma
2023 · Ke Shi, Yufei Bi, et al. · Frontiers in Pharmacology · 12
PDF
A novel prognostic model for predicting the risk of first variceal hemorrhage in patients with HBV-related cirrhosis
2023 · Qun Zhang, Shuaishuai Niu, et al. · Frontiers in Cellular and Infection Microbiology · 8
PDF
A dynamic nomogram to predict transplant-free mortality in patients with hepatitis B-related cirrhosis and overt hepatic encephalopathy
2022 · Ke Shi, Yunyi Huang, et al. · International Immunopharmacology · 6
Prevalence and risk factors of osteoporosis detected by dual-energy X-ray absorptiometry among Chinese patients with primary biliary cholangitis
2023 · Jia-Liang Chen, Yao Liu, et al. · World Journal of Gastroenterology · 4
PDF
Alterations in Gut Microbiota and Metabolism in Cirrhotic Portal Hypertension: Implications for Disease Progression
2025 · Qun Zhang, Jinghua Cui, et al. · Alimentary Pharmacology & Therapeutics · 3
Curative effect of anti-fibrosis Chinese patent medicines combined with ursodeoxycholic acid for primary biliary cholangitis: A systematic review and meta-analysis
2023 · Yufei Bi, Ke Shi, et al. · Frontiers in Pharmacology · 2
Prognostic Value of High-Density Lipoprotein Cholesterol in Patients with Overt Hepatic Encephalopathy
2024 · Ke Shi, Yufei Bi, et al. · Biomedicines · 1
Development of a nomogram to predict the risk of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis on antivirals
2023 · Ke Shi, Ping Li, et al. · Frontiers in Oncology · 1
PDF
Evaluation of LiangXue JieDu Therapy in Combination With Western Medicine for Acute-On-Chronic Liver Failure: A Systematic Review and meta-Analysis
2022 · Ke Shi, Qun Zhang, et al. · Frontiers in Pharmacology · 1
PDF
Fuzheng Jiedu Xiaoji Formula Remodelled Glycolytic Metabolism Manipulate Immune Responses in Hepatocellular Carcinoma
2024 · Wang Xianbo, Fengna Yan, et al. · SSRN Electronic Journal
Prognostic and therpeutic potential of PD-1 expression imbalance between CD8+T and regulatory T cells in advanced hepatitis B virus‐associated hepatocellular carcinoma
2023 · Fengna Yan, Bingbing Zhu, et al. · Research Square
PDF
Prevalence and risk factors of osteoporosis in patients with primary biliary cholangitis in Chinese population
2023 · Jialiang Chen, Yao Liu, et al. · Journal of Hepatology
Fuzheng Huayu Capsule Improves Survival in Patients with Hepatitis B-related Cirrhosis and Overt Hepatic Encephalopathy
2023 · Ke Shi, Yi Zhang, et al. · Journal of Integrative Medicine
PDF
Works count: 18
Citation count: 348
H-index: 7
I10-index: 6
Year
Topic
Type